The scientific interest in the management of not only T2DM but also obesity via the use of GLP-1 receptor agonist and the older one, glucose-dependent insulinotropic polypeptide (GIP), led to the development of newer agents [139,140,141]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.